The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -173,799 |
| Depreciation expense | 1,531 |
| Stock-based compensation expense | 2,610 |
| Change in fair value of the convertible loan | 120,963 |
| Non-cash interest expense | 16,568 |
| Impairment expense | 5,412 |
| Change in right-of-use asset | -2,364 |
| Prepaid expenses and other assets | -39 |
| Accounts payable and accrued liabilities | -334 |
| Accrued compensation | -89 |
| Operating lease liability | -1,028 |
| Net cash used in operating activities | -25,763 |
| Purchases of property and equipment | 542 |
| Net cash used in investing activities | -542 |
| Proceeds from issuance of term debt, net of issuance costs | 25,000 |
| Payments for taxes related to net share settlement of equity awards | 46 |
| Proceeds from exercise of stock options | 658 |
| Net cash provided by financing activities | 25,612 |
| Net change in cash, cash equivalents and restricted cash | -693 |
| Cash, cash equivalents and restricted cash, beginning of period | 14,771 |
| Cash, cash equivalents and restricted cash, end of period | 14,078 |
Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. (ARMP)